Jacobio Pharmaceuticals Group Co. Ltd.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for… Read more
Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) - Net Assets
Latest net assets as of June 2025: $867.38 Million USD
Based on the latest financial reports, Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) has net assets worth $867.38 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.29 Billion) and total liabilities ($423.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $867.38 Million |
| % of Total Assets | 67.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | -48.32% |
| 10-Year Change | N/A |
| Growth Volatility | 4.78 |
Jacobio Pharmaceuticals Group Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Jacobio Pharmaceuticals Group Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jacobio Pharmaceuticals Group Co. Ltd. (2019–2024)
The table below shows the annual net assets of Jacobio Pharmaceuticals Group Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $923.18 Million | -13.99% |
| 2023-12-31 | $1.07 Billion | -16.31% |
| 2022-12-31 | $1.28 Billion | -21.66% |
| 2021-12-31 | $1.64 Billion | -8.35% |
| 2020-12-31 | $1.79 Billion | +479.98% |
| 2019-12-31 | $-470.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jacobio Pharmaceuticals Group Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 271339100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $4.27 Billion | 462.82% |
| Total Equity | $923.18 Million | 100.00% |
Jacobio Pharmaceuticals Group Co. Ltd. Competitors by Market Cap
The table below lists competitors of Jacobio Pharmaceuticals Group Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changshu Tongrun Auto
SHG:603201
|
$122.14 Million |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
$122.17 Million |
|
Zhejiang XinNong Chemical Co Ltd Class A
SHE:002942
|
$122.21 Million |
|
Sern Kou Resources Bhd
KLSE:7180
|
$122.21 Million |
|
Silicius Real Estate SOCIMI S.A.
MC:YSIL
|
$122.08 Million |
|
Raymond Limited
NSE:RAYMOND
|
$122.08 Million |
|
Francaise de l'Energie
LSE:0RIL
|
$122.04 Million |
|
AVE Science & Technology Co Ltd
SHG:688067
|
$121.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jacobio Pharmaceuticals Group Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,073,371,000 to 923,180,000, a change of -150,191,000 (-14.0%).
- Net loss of 155,709,000 reduced equity.
- Share repurchases of 4,565,000 reduced equity.
- Other factors increased equity by 10,083,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-155.71 Million | -16.87% |
| Share Repurchases | $4.57 Million | -0.49% |
| Other Changes | $10.08 Million | +1.09% |
| Total Change | $- | -13.99% |
Book Value vs Market Value Analysis
This analysis compares Jacobio Pharmaceuticals Group Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.62 | $0.30 | x |
| 2020-12-31 | $2.35 | $0.30 | x |
| 2021-12-31 | $2.12 | $0.30 | x |
| 2022-12-31 | $1.66 | $0.30 | x |
| 2023-12-31 | $1.36 | $0.30 | x |
| 2024-12-31 | $1.17 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jacobio Pharmaceuticals Group Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -100.00%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.47x
- Recent ROE (-16.87%) is above the historical average (-30.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-377.83 Million |
| 2020 | -84.74% | -311.27% | 0.26x | 1.05x | $-1.69 Billion |
| 2021 | -18.40% | -197.10% | 0.09x | 1.05x | $-464.90 Million |
| 2022 | -28.99% | -388.38% | 0.06x | 1.23x | $-500.11 Million |
| 2023 | -33.46% | -565.36% | 0.04x | 1.36x | $-466.46 Million |
| 2024 | -16.87% | -100.00% | 0.11x | 1.47x | $-248.03 Million |
Industry Comparison
This section compares Jacobio Pharmaceuticals Group Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) | $867.38 Million | 0.00% | 0.49x | $122.14 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |